| Wissenschaftl. Titel | A Phase 1/2, First-in-Human, Open-Label, Two Part Clinical Trial of TK-8001 (MAGE-A1--Directed TCR Transduced Autologous CD8+ T-cells) in Patients With HLA-A*02:01 Genotype and Advanced Stage/Metastatic, MAGE-A1+ Solid Tumors That Either Have No Further Approved Therapeutic Alternative(s) or Are in a Non-Curable State and Have Received a Minimum of Two Lines of Systemic Therapy |
| Erkrankung |
Solide Tumore/Neoplasien:
Verschiedene solide Tumore/Neoplasien:
Zweitlinie oder später
|
| Kurzprotokoll | Kurzprotokoll |
| Links | Weiterführende Informationen (B) Weiterführende Informationen (DD) Weiterführende Informationen (NIH) |
erstellt 21.11.2022 Data entry III CCP
geändert 11.07.2023 Data entry II CCP